Radioactive ADCs in Oncology & Autoimmune Diseases

Time: 3:30 pm
day: Day One


  • Radioimmunoconjugates are not a new class of drugs but improvements in conjugation technology, choices of isotopes and antibody engineering techniques has generated new interest
  • Highlighting significant opportunities in both diagnostic and therapeutic medicine
  • Outlining a number of recent late-stage developments in this exciting field, as well as potentially important new platform technologies for the future